# US 2017/0254818 A1 · Cns-specific biomarkers for cns diseases or injuries

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0254818 A1
- Document ID: US20170254818A1
- Status: Published application
- Kind: A1
- Application number: 15/506,325
- Filed: 2015-08-24
- Published: 2017-09-07
- Earliest claimed: 2014-08-24
- Assignees: The Board of Regents of the University of Texas Sy Stem
- Inventors: William E. HASKINS; Thomas G. FORSTHUBER
- Web page: https://patentgrep.com/patent/US20170254818A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2800/285: Demyelinating diseases; Multipel sclerosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods and compositions for detecting and/or measuring biomarkers associated with compromised BBB.

## Claims

### Claim 1

A method of evaluating a patient suspected of having a central nervous system (CNS) disease comprising:
measuring the level of at least one protein biomarker or peptide biomarker selected from SEQ ID NO:1 to SEQ ID NO:544 in a biologic sample from the patient, wherein the patient is suspected of having, is at risk of developing, or has been diagnosed with a CNS disease;
classifying the subject based on the levels of at least one biomarker associated with a CNS disease or a CNS injury.

### Claim 2 (depends on 1)

The method of claim 1, further comprising measuring the level of at least one protein biomarker or peptide biomarker in a plurality of samples from the patient, each sample obtained at a different time, and determining the trajectory of an expression wave for the at least one protein biomarker or peptide biomarker measured.

### Claim 3 (depends on 1)

The method of claim 1, wherein the at least one protein comprises one or more of α-II-spectrin, synapsin-1/2/3, myelin basic protein, ubiquitin carboxyl-terminal esterase L1, calcium/calmodulin-dependent protein kinase II alpha, neurofilament light and medium, parkin 2, peroxiredoxin-1/4/5/6, 14-3-3-β/ε/ζ, synaptotagmin, enolase-1/2, guanine nucleotide binding protein α and β1, superoxide dismutase 2, internexin neuronal intermediate filament protein α, tyrosine-protein phosphatase non-receptor type substrate 1, macrophage migration inhibitory factor, proteolipid protein 1, or caspase 7, and combinations thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the peptide biomarker comprises one or more of a peptide having the amino acid sequence of SEQ ID NO:1 to 544.

### Claim 5 (depends on 1)

The method of claim 1, wherein the protein biomarker or peptide biomarker is measured using mass spectrometry.

### Claim 6 (depends on 5)

The method of claim 5, wherein the sample is labeled using isobaric labels.

### Claim 7 (depends on 6)

The method of claim 6, wherein the sample is prepared using microwave and magnetic sample preparation.

### Claim 8 (depends on 1)

The method of claim 1, wherein the protein biomarker or peptide biomarker is measured using an immunoassay.

### Claim 9 (depends on 8)

The method of claim 8, wherein the immunoassay is an ELISA or an antibody array.

### Claim 10 (depends on 1)

The method of claim 1, wherein the CNS disease is multiple sclerosis.

### Claim 11

A method of detecting a preclinical expression wave comprising measuring biomarker levels in two or more samples from a patient that were obtained at different times and determining the rate of change of biomarker expression.
